SPINAL CORD STIMULATION
Pain indications
Learn where your patients can find pain relief
through spinal cord stimulation (SCS).
Disrupting pain signals. Reclaiming comfort.
Spinal cord stimulation (SCS) is a proven, non-opioid, FDA-approved way to manage certain types of chronic pain in the upper limbs, back, legs, or feet. SCS is a small implant that works by disrupting pain signals traveling between the spinal cord and the brain.
With SCS, patients may find relief from intractable chronic pain and revitalize their lives.
SCS efficacy for chronic pain
Learn where our SCS therapy provides durable/sustainable relief from intractable chronic neuropathic pain.
Upper limb pain
100%
All upper-limb subjects were satisfied or very satisfied with DTM™ SCS at 12 months.1
Learn more about:
Leg and foot pain
86%
Diabetic peripheral neuropathy patients reported treatment success after receiving SCS therapy for 1-year.*2
Learn more about:
Back pain
93%
Back pain patients felt very satisfied or satisfied with their DTM™ SCS programming at 12 months.3
Learn more about:
Learn more about spinal cord stimulation at Medtronic Academy.
Medtronic SCS indications
Medtronic is indicated for spinal cord stimulation as an aid in the management of chronic, intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following conditions:
- Failed back syndrome (FBS) or low back syndrome or failed back
- Radicular pain syndrome or radiculopathies resulting in pain secondary to failed back surgery syndrome (FBSS) or herniated disc
- Post-laminectomy pain
- Multiple back operations
- Unsuccessful disc surgery
- Degenerative disc disease (DDD)/herniated disc pain refractory to conservative and surgical interventions
- Peripheral causalgia
- Epidural fibrosis
- Arachnoiditis or lumbar adhesive arachnoiditis
- Complex regional pain syndrome (CRPS), reflex sympathetic dystrophy (RSD), or causalgia
- Diabetic peripheral neuropathy of the lower extremities
Areas in blue are covered for pain relief by SCS based on approved FDA indications.
Access educational materials
See training opportunities for spinal cord stimulation.
*
Success rates in a population of patients treated with SCS in two studies and followed for five years.
1
White T, et al. Effect of differential target multiplexed SCS on intractable upper limb pain: A 12-month prospective study. Presented at American Society for Regional Anesthesiology and Pain Medicine (ASRA) annual meeting; November 10-11, 2023; New Orleans, LA.
2
van Beek M, Geurts JW, Slangen R, et al. Severity of neuropathy is associated with long-term spinal cord stimulation outcomes in painful diabetic peripheral neuropathy: Five-year follow-up of a prospective two-center clinical trial. Diabetes Care. 2018;41(1):32–38. doi:10.2337/dc17-0983.
3
Fishman M, Cordner H, Justiz R, et al. 12-Month results from multicenter, open-label, randomized controlled clinical trial comparing differential target multiplexed spinal cord stimulation and traditional spinal cord stimulation in subjects with chronic intractable back pain and leg pain. Pain Pract. 2021; 00: 1– 12. doi: 10.1111/papr.13066.